Kombigripp

General characteristics. Structure:

Active ingredients: 500 mg of paracetamol, 10 mg of Phenylephrinum of a hydrochloride, 2 mg of chlorpheniramine of a maleate, 30 mg of caffeine.

Excipients: starch corn, cellulose microcrystallic, calcium hydrophosphate a dihydrate, methylhydroxybenzoate, пропилгидроксибензоат, povidone (PVPK-30), magnesium stearate, talc, sodium krokhmalglikolit, dye yellow "sunset".

The combined medicine rendering the febrifugal, anesthetizing, antiedematous, vasoconstrictive and antiallergic action.

Pharmacological properties:

Pharmacodynamics. The paracetamol which is a part of drug is non-narcotic antipyretic analgetic. At reception of paracetamol decrease in products and reduction of level of prostaglandins in tissues of the central nervous system is noted, as causes the anesthetizing and febrifugal effect of medicine.

Caffeine stimulates processes of activation in a cerebral cortex, increases physical activity, improves memory and ability to concentration of attention. Use of caffeine in therapeutic doses leads to increase in physical and intellectual effeciency. Besides, caffeine exponentiates effects of nonsteroid analgetics.

Phenylephrinum a hydrochloride – artificial substitute of Epinephrinum, alpha адреномиметик. Fenilefrina a hydrochloride promotes reduction of a hyperemia and hypostasis of a mucous membrane of a nasopharynx, and also expressiveness of exudative manifestations due to reduction of permeability of a vascular wall. Fenilefrina a hydrochloride facilitates nasal breath and reduces expressiveness of a rhinorrhea a little.

Chlorpheniramine a maleate – the antiallergic medicinal substance blocking H1-gistaminove receptors. At reception of chlorpheniramine of a maleate reduction of reddening, puffiness and an itch of a mucous membrane of a nose and adnexal bosoms is noted, besides, chlorpheniramine the maleate promotes elimination of sneezing, dacryagogue, a rhinorrhea and feeling of irritation in a throat.

Pharmacokinetics. After intake, the components which are a part of drug quickly are soaked up in digestive tract. The peak of plasma concentration of paracetamol is noted 2 hours later after oral administration of drug Kombigripp. All components are metabolized preferential in a liver, metabolites are removed by kidneys.

The elimination half-life of Phenylephrinum of a hydrochloride reaches 2-3,5 hour, paracetamol – 1,5-2,5 hour, chlorpheniramine of a maleate can fluctuate from 2 to 43 hours (depending on specific features of an organism), caffeine – 3-7 hours.

Indications to use:

Kombigripp is applied as symptomatic cure for flu and acute viral diseases of respiratory tracts.

Kombigripp can be also appointed as the means facilitating symptoms, to patients with rhinitis of various etiology, including allergic rhinitis.

Route of administration and doses:

Kombigripp accept orally. Kombigripp after meal at least in 30 minutes is recommended to take a pill. The pill should be taken entirely, without breaking also not chewing, washing down with a large amount of water. Kombigripp determines duration of therapy and a dose of drug the doctor.

Reception of 1/2-1 tablet three-four times a day is recommended to children from 6 to 12 years.

Reception of 1-2 tablets to four times a day is recommended to adults and teenagers from 12 years. An interval between administrations of drug Kombigripp has to make not less than four hours.

The maximum admissible daily dose of drug Kombigripp for adults makes 8 tablets.

The maximum recommended duration of therapy makes 7 days. At preservation of symptoms after end of a course of treatment it is necessary to see a doctor.

Features of use:

Drug can reduce mental and/or physical abilities which are necessary when performing potentially dangerous tasks, such as control of vehicles or work with mechanisms. Phenylephrinum can cause acceleration of pulse, dizziness or strong heartbeat; patients have to be warned about it.

Pregnant women are forbidden to use this medicine. In case of need administration of drug Kombigripp in the period of a lactation, breastfeeding needs to be stopped temporarily.

With care to apply at diseases of a liver, heart and vessels.

During treatment to exclude alcohol intake.

Side effects:

Drug Kombigripp is usually not bad transferred by patients. However it is not necessary to exclude a possibility of development of such undesirable phenomena:

- from gepatobiliarny system and a digestive tract: decrease or lack of appetite, vomiting, nausea, diarrhea, lock, increase in activity of liver enzymes. Development of a hepatotoxic action is in some cases possible.

- from heart, vessels and system of blood: agranulocytosis, tachycardia, arrhythmia, thrombocytopenia, anemia, increase in arterial pressure.

- from a nervous system: concern, the excited state, sleeplessness, dizziness, drowsiness, consciousness misting.

Allergic reactions: small tortoiseshell, bronchospasm, acute anaphylaxis, Quincke's disease.

Interaction with other medicines:

Kombigripp it is not necessary to accept with the medicines containing non-steroidal anti-inflammatory drugs, and also potentially hepatotoxic substances.

Caffeine exponentiates effect of indirect anticoagulants and non-narcotic analgesics.

At the combined use of caffeine with the medicines oppressing the central nervous system decrease in efficiency of the last is noted. Kombigripp increases absorption of ergotamine in digestive tract.

Barbiturates at the combined use reduce antipyretic activity of paracetamol.

Interaction of Phenylephrinum with other pressor amines and monoamine oxidase inhibitors can lead to increase in arterial pressure. Monoamine oxidase inhibitors can prolong effect of antihistaminic drugs.

Chlorpheniramine the maleate is incompatible from Kanamycinum sulfate, Calcii chloridum, phenobarbital, noradrenaline.

Contraindications:

Kombigripp do not appoint to patients with the known hypersensitivity to any component of drug, and also medicinal substances of group of non-narcotic analgesics.

It is not necessary to appoint Kombigripp to the patients receiving therapy by monoamine oxidase inhibitors.

Kombigripp do not apply to therapy of the patients suffering from severe forms of a renal and liver failure, the expressed atherosclerosis, arterial hypertension, coronary heart disease and a diabetes mellitus.

Drug is not recommended to be used at a prostatauxe, acute pancreatitis and hepatitis, alcoholism, ventricular tachycardia, disturbance of cordial conductivity and fibrinferment of peripheral arteries.

Purpose of drug Kombigripp is contraindicated to children aged up to 6 years.

Overdose:

In high doses paracetamol can make sick, vomiting, anorexia, pallor of integuments. At considerable overdose development of a gepatonekroz, metabolic acidosis and coma is noted.

High doses of caffeine lead to development of concern, a headache, dizziness, a tremor of extremities and sleeplessnesses.

Reception of Phenylephrinum of a hydrochloride in the doses exceeding therapeutic leads to increase in risk of development of side effects - long increase in arterial pressure, tachycardia or reflex bradycardia.

The overdose of chlorpheniramine of a maleate can cause the state varying from excited (concern and spasms) to suppressed. Development of atropinopodobny symptoms is also possible.
At overdose wash out a stomach and appoint enterosorbentny means.

At development of symptoms of overdose of paracetamol appoint a gastric lavage and introduction of N-Acetylcysteinum or methionine. In case of need appoint the oxygenotherapy, symptomatic means and actions directed to maintenance of water and electrolytic balance and functions of a liver and cardiovascular system.

Storage conditions:

To store in the unavailable to children, dry and protected from light place at a temperature of 15-25 degrees Celsius.

Issue conditions:

Without recipe

Packaging:

The tablets Kombigripp packaged on 8 pieces in strip planimetric packagings 10 strip planimetric packagings are enclosed in a cardboard pack.